**REFERENCES (Supplementary)**

S1. Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. *QJM.* 2016;109(1):27-33.

S2. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. *Semin Nephrol.* 2013;33(6):508-530.

S3. Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. *Am J Med Sci.* 2016;352(2):177-190.

S4. Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. *Annu Rev Med.* 2013;64:307-324.

S5. Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. *Annu Rev Pathol.* 2017;12:25-52.

S6. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. *J Clin Invest.* 2010;120(10):3702-3712.

S7. Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). *Semin Thromb Hemost.* 2014;40(4):422-430.

S8. Abdul Ajees A, Gunasekaran K, Volanakis JE, Narayana SV, Kotwal GJ, Murthy HM. The structure of complement C3b provides insights into complement activation and regulation. *Nature.* 2006;444(7116):221-225.

S9. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood.* 2012;119(18):4182-4191.

S10. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. *Blood.* 2008;112(13):4948-4952.

S11. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated haemolytic uraemic synbdrome: prognostic significance of genetic background. *Clinical J Am Soc Nephrol.* 2006;1:88-99.

S12. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. *Nature reviews Nephrology.* 2011;7(1):23-35.

S13. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. *Am J Transpl.* 2010;10(7):1517-1523.

S14. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clinical J Am Soc Nephrol.* 2010;5(10):1844-1859.

S15. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. *Am J Kidney Dis.* 2003;42(5):1058-1068.

S16. Nilsson SC, Nita I, Mansson L, et al. Analysis of binding sites on complement factor I that are required for its activity. *J Biol Chem.* 2010;285(9):6235-6245.

S17. Sanchez-Gallego JI, Groeneveld TW, Krentz S, Nilsson SC, Villoutreix BO, Blom AM. Analysis of binding sites on complement factor I using artificial N-linked glycosylation. *J Biol Chem.* 2012;287(17):13572-13583.

S18. Tsiftsoglou SA, Sim RB. Human complement factor I does not require cofactors for cleavage of synthetic substrates. *J Immunol.* 2004;173(1):367-375.

S19. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med.* 2013;368(23):2169-2181.

S20. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. *Kidney Int.* 2015;87(5):1061-1073.

S21. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. *Am J Transpl.* 2012;12(12):3337-3354.

S22. Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. *Nat Genet.* 2013;45(11):1366-1370.

S23. Xue X, Wu J, Ricklin D, et al. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. *Nat Struct Mol Biol.* 2017;24(8):643-651.

S24. Heyda J, Mason PE, Jungwirth P. Attractive interactions between side chains of histidine-histidine and histidine-arginine-based cationic dipeptides in water. *J Phys Chem B.* 2010;114(26):8744-8749.

S25. Collard CD, Bukusoglu C, Agah A, et al. Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. *Am J Physiol.* 1999;276(2 Pt 1):C450-458.

S26. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. *Clinical J Am Soc Nephrol.* 2018;13(2):300-317.

S27. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. *PLoS Med.* 2011;8(3):e1001013.

S28. Hoffman-Andrews L. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. *J Law Biosci.* 2017;4(3):648-657.

S29. Siner JI, Samelson-Jones BJ, Crudele JM, et al. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. *JCI Insight.* 2016;1(16):e89371.